Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial
Authors
Michele Del Vecchio (ORCID: https://orcid.org/0000-0001-9060-2512)
John M. Kirkwood (ORCID: https://orcid.org/0000-0002-3570-4476)
Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial
Michele Del Vecchio, John M. Kirkwood, Ayman Hamdy Nassar, Peter Mohr et al.
Citations
6 citations
Journal
European Journal of Cancer
Topics
Cutaneous Melanoma Detection and Management
Field-Weighted Citation Impact (FWCI)
6.27
article
Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial
Michele Del Vecchio, John M. Kirkwood, Ayman Hamdy Nassar, Peter Mohr, Jeffrey S. Weber, Christoph Höeller, Jean‐Jacques Grob, Georgina Venetia Long, Jennifer Lord‐Bessen, Swetha Srinivasan, Fiona Taylor, Rachael Lawrance, Hannah Fairbanks, Federico Campigotto
article en
6 citations
Abstract
No abstract available for this paper.
Publication Tag
European Journal of CancerVol. 220
Institutions
The University of Sydney (AU), Aix-Marseille Université (FR), Royal North Shore Hospital (AU), NYU Langone Health (US), Adelphi Group (United Kingdom) (GB), Bristol-Myers Squibb (United States) (US), UPMC Health System (US), Melanoma Institute Australia (AU), Bristol-Myers Squibb (United Kingdom) (GB), Elbe Kliniken Stade-Buxtehude (DE), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), Adelphi Laboratory Center (US), Hôpital de la Timone (FR), Medical University of Vienna (AT)